Vir Biotechnology, Inc. VIR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $283.04M-23.1% | $241.07M-24.4% | $179.26M-32.2% | $306.28M-3.4% | $368M+104% | ||
| $196.28M-62.1% | $228.75M-66.3% | $327.75M-55.7% | $387.65M-54.4% | $517.37M-47.5% | ||
| $522.99M-43.9% | $514.08M-50.7% | $545.68M-47.9% | $735.71M-39.0% | $932.21M-23.2% | ||
| $53.16M-13.8% | $55.62M-12.0% | $58.2M-10.2% | $60.8M-8.0% | $61.68M-33.3% | ||
| $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | ||
| $7.78M-3.7% | $7.85M-3.3% | $7.92M-58.9% | $8M-57.7% | $8.07M-64.1% | ||
| $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% | $1.31B-27.1% | ||
| $34.33M+67.5% | $32.61M+36.5% | $27.89M+10.9% | $28.35M+32.1% | $20.5M-30.4% | ||
| $73.56M-46.4% | $92.82M-22.4% | $75.22M-35.8% | $105M+8.9% | $137.29M+45.9% | ||
| $212.82M-19.4% | $237.55M-4.4% | $223.36M-13.3% | $245.06M+3.9% | $263.91M+7.0% | ||
| 300M0.0% | 300M+2,142,757% | 300M0.0% | 300M0.0% | 300M0.0% | ||
| -$1.32B-50.3% | -$1.2B-57.6% | -$1.15B-76.3% | -$991.71M-125% | -$880.75M-191% | ||
| $812.77M-22.1% | $765.28M-33.5% | $796.1M-35.8% | $947.47M-33.9% | $1.04B-32.5% | ||
| $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% | $1.31B-27.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Vir Biotechnology, Inc. cover its short-term obligations?
- Its current ratio is 7.11 — current assets exceed current liabilities.
- Where does Vir Biotechnology, Inc.'s balance sheet data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.